Skip Navigation



JAC Advance Access published online on October 16, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg446
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/5/790    most recent
dkg446v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Sun, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Sun, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Original article

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

Ying Zhang 1 , Mary Margaret Wade 1 , Angelo Scorpio 1 , Hao Zhang 1 , and Zhonghe Sun 1

1 Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA

Received 18 June 2003 ; revised 14 August 2003 ; accepted 17 August 2003

Abstract

Pyrazinamide is an important sterilizing drug that shortens tuberculosis (TB) therapy. However, the mechanism of action of pyrazinamide is poorly understood because of its unusual properties. Here we show that pyrazinoic acid, the active moiety of pyrazinamide, disrupted membrane energetics and inhibited membrane transport function in Mycobacterium tuberculosis. The preferential activity of pyrazinamide against old non-replicating bacilli correlated with their low membrane potential and the disruption of membrane potential by pyrazinoic acid and acid pH. Inhibitors of membrane energetics increased the antituberculous activity of pyrazinamide. These findings shed new light on the mode of action of pyrazinamide and may help in the design of new drugs that shorten therapy.

Keywords: tuberculosis, mechanism of action, membrane potential, M. tuberculosis
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
T. Gumbo, C. S. W. Siyambalapitiyage Dona, C. Meek, and R. Leff
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3197 - 3204.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
P. Gu, L. Constantino, and Y. Zhang
Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide
J. Med. Microbiol., September 1, 2008; 57(9): 1129 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
C. D. Sohaskey
Nitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration
J. Bacteriol., April 15, 2008; 190(8): 2981 - 2986.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
H. Eoh, A. C. Brown, L. Buetow, W. N. Hunter, T. Parish, D. Kaur, P. J. Brennan, and D. C. Crick
Characterization of the Mycobacterium tuberculosis 4-Diphosphocytidyl-2-C-Methyl-D-Erythritol Synthase: Potential for Drug Development
J. Bacteriol., December 15, 2007; 189(24): 8922 - 8927.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. C. Ngo, O. Zimhony, W. J. Chung, H. Sayahi, W. R. Jacobs Jr., and J. T. Welch
Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2430 - 2435.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Li and Y. Zhang
PhoU Is a Persistence Switch Involved in Persister Formation and Tolerance to Multiple Antibiotics and Stresses in Escherichia coli
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2092 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Ibrahim, K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, V. Jarlier, and N. Veziris
Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1011 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. G. Dover, A. Alahari, P. Gratraud, J. M. Gomes, V. Bhowruth, R. C. Reynolds, G. S. Besra, and L. Kremer
EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1055 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
O. Zimhony, C. Vilcheze, M. Arai, J. T. Welch, and W. R. Jacobs Jr.
Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 752 - 754.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. T. Byrne, S. M. Denkin, and Y. Zhang
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis
J. Antimicrob. Chemother., February 1, 2007; 59(2): 313 - 316.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. M. Wade and Y. Zhang
Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro
J. Antimicrob. Chemother., November 1, 2006; 58(5): 936 - 941.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Barco, R. F. Cardoso, R. D. C. Hirata, C. Q. F. Leite, J. R. Pandolfi, D. N. Sato, M. L. Shikama, F. F. de Melo, E. M. Mamizuka, P. A. Z. Campanerut, et al.
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil
J. Antimicrob. Chemother., November 1, 2006; 58(5): 930 - 935.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. d. A. Cordeiro, R. S. N. Brilhante, M. F. G. Rocha, M. A. B. Fechine, Z. P. d. Camargo, and J. J. C. Sidrim
In vitro inhibitory effect of antituberculosis drugs on clinical and environmental strains of Coccidioides posadasii
J. Antimicrob. Chemother., September 1, 2006; 58(3): 575 - 579.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Martin, H. Takiff, P. Vandamme, J. Swings, J. C. Palomino, and F. Portaels
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide
J. Antimicrob. Chemother., August 1, 2006; 58(2): 327 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. F. Warner and V. Mizrahi
Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy
Clin. Microbiol. Rev., July 1, 2006; 19(3): 558 - 570.
[Abstract] [Full Text] [PDF]

Home page
 MicrobiologyHome page
C. D. Sohaskey
Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide
Microbiology, November 1, 2005; 151(11): 3803 - 3810.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. T. McCammon, J. S. Gillette, D. P. Thomas, S. V. Ramaswamy, I. I. Rosas, E. A. Graviss, J. Vijg, and T. N. Quitugua
Detection by Denaturing Gradient Gel Electrophoresis of pncA Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates from the United States-Mexico Border Region
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2210 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
M. M. Wade and Y. Zhang
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
J. Med. Microbiol., August 1, 2004; 53(8): 769 - 773.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Somoskovi, M. M. Wade, Z. Sun, and Y. Zhang
Iron enhances the antituberculous activity of pyrazinamide
J. Antimicrob. Chemother., February 1, 2004; 53(2): 192 - 196.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.